Astellas' Drug Discovery Strategy: Focus on Oncology. Yamanouchi Pharmaceutical Co., Ltd. Fujisawa Pharmaceutical Co., Ltd.
Overview of R&D Pipeline (pdf 94KB) [January 29, 2016] Main Text end. Financial Information; Stock & Rating Information. Overview of R&D Pipeline of Astellas Pharma.
Astellas Pharma Inc. - Product Pipeline. and its locations and subsidiaries - The report reviews current pipeline of Astellas Pharma Inc.’s. (1 user pdf.
0 Our Pipeline Bringing innovative therapeutics to patients. July 10, 2014 Sef Kurstjens, M.D., Ph.D. Chief Medical Officer, Astellas Pharma Inc. A Astellas Pharma US, Inc. is committed to providing patients, customers, community and employees with a bright future by changing tomorrow. Our commitment is.
Yamanouchi and Fujisawa finalize merger agreement. The new company to be named ‘Astellas Pharma Inc.
Based on the goal of delivering innovative and reliable pharmaceutical products to cancer patients for whom no effective treatments exist, Astellas is. 全部 DOC PPT TXT PDF XLS 百度文库 专业资料 医药卫生 安斯泰来_pipeline_en_医药卫生_专业资料 暂无评价. Drug discovery research 7 Status of Astellas’ Pipeline. R&D Pipeline (February 2014) - Astellas Pharma World Wide:研发管道(2014二月)-安斯泰来制药世界管道,World,Wide,2014,world,wide,WORLD 文档格式:.pdf 11页. Astellas Pharma: Pipeline, Products, Performance, Potential. Date: January 1, 2010 Pages: 146 Price: US$ 1,040.00 ID: AAA86A7FFE4EN.
News release. 2. 00. May. 2. Yamanouchi Pharmaceutical Co., Ltd. Fujisawa Pharmaceutical Co., Ltd. Business philosophy, brand mark, and corporate message of Astellas. News release. 2. 00. September. 3. Nogimori M. Astellas Pharma Inc.
December. 4. Astellas Pharma Inc. Announcement of VISION 2.
News release. 2. 00. December. 5. Tsukamoto S. Astellas Day—Research Part. Astellas Pharma Inc. September. 6. Yamada Y, Hiraki M, Sasajima K, Matsugaki N, Igarashi N, Amano Y, et al. AR- NE3. A, a new macromolecular crystallography beamline for pharmaceutical applications at the photon factory. AIP Conf Proc. 2.
Miyoshi S, Mitsuoka K, Nishimura S, Veltkamp SA. Radioisotopes in drug research and development: focus on positron emission tomography. In: Singh N, editor. Radioisotopes—Applications in Bio- Medical Science. Rijeka: In. Tech—Open Access Publisher; 2. Yuri M, Hiramoto M, Naito M, Matsumoto M, Matsumoto S, Morita S, et al.
Identification and relative quantitation of an orphan G- Protein coupled receptor SREB2 (GPR8. J Proteome Res. 2. Pub. Med]9. Kuroda D, Shirai H, Kobori M, Nakamura H. Structural classification of CDR- H3 revisited: a lesson in antibody modeling. Proteins. 2. 00. 8; 7. Pub. Med]1. 0. Kuroda D, Shirai H, Kobori M, Nakamura H. Systematic classification of CDR- L3 in antibodies: implications of the light chain subtypes and the VL–VH interface.
Proteins. 2. 00. 9; 7. Pub. Med]1. 1. Astellas Pharma Inc. Regeneron Pharmaceuticals, Inc. Astellas licenses Regeneron's Veloc. Immune® technology for discovering human monoclonal antibodies.
News release. 2. 00. March. 1. 2. Astellas Pharma Inc. Astellas to acquire Agensys, Inc.
News release. 2. 00. November. 1. 3. Nogimori M.
Astellas' growth strategy. Astellas Pharma Inc. November. 1. 4. Nakahara T, Takeuchi M, Kinoyama I, Minematsu T, Shirasuna K, Matsuhisa A, et al. YM1. 55, a novel small- molecule survivin suppressant, induces regression of established human hormone- refractory prostate tumor xenografts. Cancer Res. 2. 00. Pub. Med]1. 5. Yamanaka K, Nakahara T, Yamanouchi T, Kita A, Takeuchi M, Kiyonaga F, et al.
Antitumor activity of YM1. Clin Cancer Res. 2. Pub. Med]1. 6. Kudoh M, Susaki Y, Ideyama Y, Nanya T, Mori M, Shikama H, et al. Inhibitory effect of a novel non- steroidal aromatase inhibitor, YM5. MCF- 7 human breast cancer cell. J Steroid Biochem Mol Biol.
Pub. Med]1. 7. Kinoyama I, Taniguchi N, Toyoshima A, Nozawa E, Kamikubo T, Imamura M, et al. R,5. S)- 4- [4- Cyano- 3- (trifluoromethyl)phenyl]- 2,5- dimethyl- N- [6- (trifluoromethyl)pyridin- 3- yl]piperazine- 1- carbox amide (YM5. J Med Chem. 2. 00. Pub. Med]1. 8. Christensen CM, Grossman JH, Hwang J. The Innovator's Prescription: A Disruptive Solution for Health Care. New York: Mc. Graw- Hill; 2.
U. S. Food and Drug Administration. In vitro companion diagnostic devices, Draft guidance for industry and Food and Drug Administration staff. July. 2. 0. U. S. Food and Drug Administration. FDA approves Zelboraf and companion diagnostic test for late- stage skin cancer. FDA news release.
August. 2. 1. U. S. Food and Drug Administration. FDA approves Xalkori with companion diagnostic for a type of late- stage lung cancer. FDA news release.
August. 2. 2. Kuromitsu S, Mori M, Shimada I, Kondoh Y, Shindoh N, Soga T, et al. Anti- tumor activity of ASP3. ALK inhibitor. Proceedings of the American Association for Cancer Research 1.
Annual Meeting; 2. Abstract #2. 82. 1)2. Kuromitsu S, Mori M, Shimada I, Kondoh Y, Shindoh N, Soga T, et al. Tumor regression induced by ASP3.
ALK inhibitor, in experimental human lung tumor models. Proceedings of the 7.
Annual Meeting of the Japanese Cancer Association; 2. Abstract #P- 1. 32. Astellas Pharma Inc. Astellas Pharma Inc. OSI Pharmaceuticals, Inc.
News release. 2. 01. May. 2. 5. Thelemann A, Petti F, Griffin G, Iwata K, Hunt T, Settinari T, et al.
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics. Pub. Med]2. 6. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non- small cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2. 00. Pub. Med]2. 7. Thomson S, Petti F, Sujka- Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal- like non- small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Clin Exp Metastasis. Pub. Med]2. 8. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial–mesenchymal transitions in development and disease.
Cell. 2. 00. 9; 1. Pub. Med]2. 9. Thomson S, Petti F, Sujka- Kwok I, Mercado P, James Bean J, Monaghan M, et al. A systems view of epithelial–mesenchymal transition signaling states. Clin Exp Metastasis. PMC free article][Pub.
Med]3. 0. Buck E, Eyzaguirre A, Rosenfeld- Franklin M, Thomson S, Mulvihill M, Barr S, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin- like growth factor receptors. Cancer Res. 2. 00. Pub. Med]3. 1. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulin- like growth factor- 1 receptor (IGF- 1.
R): rationale for cotargeting IGF- 1. R and IR in cancer. Mol Cancer Ther. 2.
Pub. Med]3. 2. OSI Pharmaceuticals, Inc. AVEO Pharmaceuticals, Inc. OSI Pharmaceuticals, Inc. AVEO. News release.
December. 3. 3. Pasquetto MV, Vecchia L, Covini D, Digilio R, Scotti C. Targeted drug delivery using immunoconjugates: principles and applications. J Immunother. 2. 01. Pub. Med]3. 4. Satpayev D, Torgov M, Yang P, Morrison K, Shostak Y, Raitano A, et al. Development of AGS- 2. M6. E, a novel antibody drug conjugate (ADC) targeting nectin- 4 for the treatment of solid tumors. Proceedings of the American Association for Cancer Research 1.
Annual Meeting; 2. Abstract #2. 83. 2)3. Antonarakis ES, Cardicci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca- Maxwell K, et al. Phase I rapid dose- escalation study of AGS- 1.
C4. D4, a human anti- PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration- resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. PMC free article][Pub. Med]3. 6. Wolpin BM, O'Reilly EM, Ko YJ, Rocha Lima MS, Spratlin JL, Macarulla T, et al.
Improved 6- month survival rate in subjects with prostate stem cell antigen (PSCA) positive tumours in a global, randomized phase 2 trial comparing gemcitabine vs. Ags- 1c. 4d. 4 (asp. PC) Eur J Cancer. Suppl 1): S4. 69. Abstract #6. 59. 1)3. Masuoka Y, Shindoh N, Inamura N.
Histone deacetylase inhibitors from microorganisms: the Astellas experience. In: Petersen F, Amstutz R, editors. Progress in Drug Research Vol. Natural Compounds as Drugs. Vol. II. Basel: Birkhäuser Verlag AG; 2.
Pub. Med]3. 8. Rodrigues- Paredes M, Estellier M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2. 01. 1; 1. Pub. Med]3. 9. Kyoto University and Astellas Pharma Inc. Kyoto University and Astellas co- research at the Innovation Center for Immunoregulation Technologies and Drugs of Next Generation. News release. 2. 00.